Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Persistent losses ⢠Material leverage ADPT pairs strong gross margins and ample liquidity with persistent operating losses, heavy R&D/SG&A, meaningful leverage, and a valuation that exceeds current profitability expectations.
Price Behavior
Key Price Behavior Insights: ⢠Below SMA ⢠Repeated lower highs ⢠Support holding tests Support Level: $12.40â$12.80 Resistance Level: $14.80 ADPT is short-term bearish: trading about 6% below its last-month 21-day SMA with repeated lower highs and pressure toward the $12.4â$12.8 support bandâclose above $14.8 would resume upside, while a drop below $12.4 confirms continuation of the near-term downtrend.
Sentiment & News
Key News Insights: ⢠Heavy insider selling ⢠Institutional trimming ⢠Strong revenue/price Adaptive Biotechnologies saw concentrated insider and institutional selling in MarchâApril 2026 despite strong revenue growth and roughly 70% Y/Y share gains, with many disposals tied to option exercises or tax events.
AI Summary
ADPT has shifted from an R&Dâonly biotech to a deârisked commercial diagnostics play where a cashâflow positive MRD (clonoSEQ) franchise should now anchor nearâterm valuation, making the investment case hinge on scaling MRD volumes, preserving ASPs, and converting the pharma backlog into billable revenue. Key risk: loss of payer coverage or ASP compressionâor failure to sustain MRD cash flowâwould quickly force dilutive financing or a steep reârating given substantial debt and remaining corporate losses.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |